Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;41(12):4076-4087.
doi: 10.1002/hed.25955. Epub 2019 Sep 14.

Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease

James E Han  1 , Sun K Yi  1 , Steven Wang  2 , Audrey Erman  2 , Shethal Bearelly  2 , Simran Sindhu  3 , Jared R Robbins  1 , Julie Bauman  3 , Charles C Hsu  1
Affiliations

Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease

James E Han et al. Head Neck. 2019 Dec.

Abstract

Background: Neoadjuvant chemotherapy (NAC) trials in endemic regions of nasopharyngeal carcinoma (NPC) found improved survival, but studies are lacking in nonendemic regions. We assessed whether adding NAC to concurrent chemoradiation (CRT) improves overall survival (OS), especially in high-risk nonendemic patients.

Methods: Definitively treated NPC patients (n = 5424) from the National Cancer Database were analyzed for predictors of NAC and NAC effects on OS with multivariate Cox proportional hazards analysis (multivariate analysis [MVA]). Propensity score matched (1:2) survival analysis of NAC (n = 968) and CRT alone (n = 1914) was also performed. Effects on OS were stratified by risk group.

Results: On MVA, NAC-improved OS among the total cohort (hazard ratio [HR] 0.89, P = .049), particularly among stratified keratinizing histology (HR 0.82, P = .015) and N3 disease (HR 0.73, P = .046). Among propensity matched patients, NAC improved OS in patients with N3 disease (n = 336; HR 0.71, P = .046).

Conclusions: NAC may improve OS among nonendemic NPC patients at higher risk of distant micrometastases, particularly N3 disease and those with unfavorable histology.

Keywords: chemoradiation; head and neck cancer; nasopharyngeal carcinoma; neoadjuvant chemotherapy; radiation therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Torre LA, Freddie B, Siegel RL, Jacques F, Joannie L, Ahmedin J. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
    1. Gurtsevitch VE, Senyuta NB, Ignatova AV, et al. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions. J Gen Virol. 2017;98(8):2118-2127.
    1. Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol. 1986;33(3):194-197.
    1. Bedwinek JM, Perez CA, Keys DJ. Analysis of failures after definitive irradiation for epidermoid carcinoma of the nasopharynx. Cancer. 1980;45(11):2725-2729.
    1. Hoppe RT, Goffinet DR, Bagshaw MA. Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy. Cancer. 1976;37(6):2605-2612.

LinkOut - more resources